A Phase 1 interventional study of Vonoprazan and Vonoprazan in Healthy Volunteers, sponsored by Phathom Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-29.
Sponsored by Phathom Pharmaceuticals, Inc. · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing vonoprazan in Gastroesophageal Reflux — 5 open to participants now, 5 under way, 1 of them phase 3. vonoprazan · Gastroesophageal Reflux.
Among the 16 studies testing vonoprazan in Gastroesophageal Reflux, this one is the 13th largest by enrollment, is one of 2 that started in 2022, is one of 5 in phase 1, and was the 8th registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
Browse Gastroesophageal Reflux studies →5 of the 16 studies testing vonoprazan in Gastroesophageal Reflux are open now, in 4 countries. Recruiting first, the newest first:
Phathom Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Asian Institute of Gastroenterology, India · Sites in India
Ages 18–75
Asian Institute of Gastroenterology, India · Sites in India
Ages 18–75
Tanta University · Sites in Egypt
Ages 17–60
Fu Jen Catholic University Hospital · Sites in Taiwan
Ages 20–75
By country, each count listing its studies:
vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →
Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 118 across the 16 interventional studies. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 16 have an industry lead sponsor. The 10 most frequent:
Phathom Pharmaceuticals, Inc. is the lead sponsor of 15 studies on the registry; 2 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 11 (100%) have results posted.
Phathom Pharmaceuticals, Inc. has 4 studies filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
2 of the studies testing vonoprazan in Gastroesophageal Reflux that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07752407Phase 3Phathom Pharmaceuticals, Inc.A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks | 2027-10-20 |
| NCT06953986Asian Institute of Gastroenterology, IndiaA Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks | 2026-11-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies testing vonoprazan in Gastroesophageal Reflux, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the bioavailability (BA) of a single oral dose of vonoprazan 20 mg sprinkle capsule, either sprinkled on pudding or on applesauce, relative to a vonoprazan 20 mg tablet in healthy participants.
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to Treatment Sequence 1 will receive vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of pudding on Day 1 of Treatment Period 1, vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of applesauce on Day 1 of Treatment Period 2, and vonoprazan 20 mg as a tablet on Day 1 of Treatment Period 3.
Drug: Vonoprazan
Participants assigned to Treatment Sequence 2 will receive vonoprazan 20 mg as a tablet on Day 1 of Treatment Period 1, vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of pudding on Day 1 of Treatment Period 2, and vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of applesauce on Day 1 of Treatment Period 3.
Drug: Vonoprazan
Participants assigned to Treatment Sequence 3 will receive vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of applesauce on Day 1 of Treatment Period 1, vonoprazan 20 mg as a tablet on Day 1 of Treatment Period 2, and vonoprazan 20 mg as a sprinkle capsule on 1 tablespoon of pudding on Day 1 of Treatment Period 3.
Drug: Vonoprazan
Orally via tablet
Orally via sprinkle pellets
Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan
Time frame: Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.
Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan
Time frame: Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.
Maximum Observed Plasma Concentration (Cmax) of Vonoprazan
Time frame: Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.
Time to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan
Time frame: Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.
Terminal Phase Half-life (t1/2) of Vonoprazan
Time frame: Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.
Apparent Total Body Clearance (CL/F) of Vonoprazan
Time frame: Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.
Apparent Volume of Distribution (Vz/F) of Vonoprazan
Time frame: Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.
Terminal Elimination Rate Constant (λz) of Vonoprazan
Time frame: Day 1 of each 3-day Treatment Period: Within 0.25 hours pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose.
27 participants were randomized in a 1:1:1 ratio to 1 of 3 treatment sequences at 1 site in the United States.
| Milestone | Vonoprazan 20 mg: Treatment Sequence 1 | Vonoprazan 20 mg: Treatment Sequence 2 | Vonoprazan 20 mg: Treatment Sequence 3 |
|---|---|---|---|
| Started | 9 | 9 | 9 |
| Completed treatment a (vonoprazan 20 mg sprinkle capsule on pudding) | 9 | 8 | 9 |
| Completed treatment b (vonoprazan 20 mg sprinkle capsule on applesauce) | 9 | 8 | 9 |
| Completed treatment c (vonoprazan 20 mg tablet) | 9 | 9 | 9 |
| Completed | 9 | 8 | 9 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| ng•h/mL | Treatment A: Vonoprazan 20 mg Sprinkle Capsule on Pudding | Treatment B: Vonoprazan 20 mg Sprinkle Capsule on Applesauce | Treatment C: Vonoprazan 20 mg Tablet |
|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan | 228 ± 44.9 | 216 ± 46.0 | 219 ± 47.3 |
| ng•h/mL | Treatment A: Vonoprazan 20 mg Sprinkle Capsule on Pudding | Treatment B: Vonoprazan 20 mg Sprinkle Capsule on Applesauce | Treatment C: Vonoprazan 20 mg Tablet |
|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan | 238 ± 43.2 | 227 ± 43.1 | 231 ± 44.4 |
| ng/mL | Treatment A: Vonoprazan 20 mg Sprinkle Capsule on Pudding | Treatment B: Vonoprazan 20 mg Sprinkle Capsule on Applesauce | Treatment C: Vonoprazan 20 mg Tablet |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Vonoprazan | 23.1 ± 44.2 | 22.4 ± 41.9 | 22.3 ± 45.3 |
| hours | Treatment A: Vonoprazan 20 mg Sprinkle Capsule on Pudding | Treatment B: Vonoprazan 20 mg Sprinkle Capsule on Applesauce | Treatment C: Vonoprazan 20 mg Tablet |
|---|---|---|---|
| Time to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan | 2.00 (1.50 to 6.00) | 2.01 (1.00 to 6.00) | 2.00 (1.50 to 6.02) |
| hours | Treatment A: Vonoprazan 20 mg Sprinkle Capsule on Pudding | Treatment B: Vonoprazan 20 mg Sprinkle Capsule on Applesauce | Treatment C: Vonoprazan 20 mg Tablet |
|---|---|---|---|
| Terminal Phase Half-life (t1/2) of Vonoprazan | 7.50 ± 19.5 | 7.20 ± 18.4 | 7.29 ± 16.0 |
| litres/h | Treatment A: Vonoprazan 20 mg Sprinkle Capsule on Pudding | Treatment B: Vonoprazan 20 mg Sprinkle Capsule on Applesauce | Treatment C: Vonoprazan 20 mg Tablet |
|---|---|---|---|
| Apparent Total Body Clearance (CL/F) of Vonoprazan | 83.9 ± 43.2 | 88.1 ± 43.1 | 86.6 ± 44.4 |
| litres | Treatment A: Vonoprazan 20 mg Sprinkle Capsule on Pudding | Treatment B: Vonoprazan 20 mg Sprinkle Capsule on Applesauce | Treatment C: Vonoprazan 20 mg Tablet |
|---|---|---|---|
| Apparent Volume of Distribution (Vz/F) of Vonoprazan | 908 ± 37.6 | 915 ± 33.4 | 911 ± 38.5 |
| 1/h | Treatment A: Vonoprazan 20 mg Sprinkle Capsule on Pudding | Treatment B: Vonoprazan 20 mg Sprinkle Capsule on Applesauce | Treatment C: Vonoprazan 20 mg Tablet |
|---|---|---|---|
| Terminal Elimination Rate Constant (λz) of Vonoprazan | 0.0924 ± 19.5 | 0.0963 ± 18.4 | 0.0951 ± 16.0 |
Collected over Day 1 to Day 31. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A: Vonoprazan 20 mg Sprinkle Capsule on Pudding | 0/26 (0%) | 0/26 (0%) | 2/26 (7.7%) |
| Treatment B: Vonoprazan 20 mg Sprinkle Capsule on Applesauce | 0/26 (0%) | 0/26 (0%) | 2/26 (7.7%) |
| Treatment C: Vonoprazan 20 mg Tablet | 0/27 (0%) | 0/27 (0%) | 4/27 (14.8%) |
| Event | Treatment A: Vonoprazan 20 mg Sprinkle Capsule on Pudding | Treatment B: Vonoprazan 20 mg Sprinkle Capsule on Applesauce | Treatment C: Vonoprazan 20 mg Tablet |
|---|---|---|---|
| HeadacheNervous system disorders | 0/26 | 2/26 | 0/27 |
| Arthropod biteInjury, poisoning and procedural complications | 1/26 | 0/26 | 0/27 |
| Skin lacerationInjury, poisoning and procedural complications | 1/26 | 0/26 | 0/27 |
| Muscle contractions involuntaryNervous system disorders | 0/26 | 0/26 | 1/27 |
| Abdominal discomfortGastrointestinal disorders | 0/26 | 0/26 | 1/27 |
| Oral mucosal rougheningGastrointestinal disorders | 0/26 | 0/26 | 1/27 |
| SARS-CoV-2 test positiveInvestigations | 0/26 | 0/26 | 1/27 |
| Age, Continuous(years) | Vonoprazan 20 mg: Treatment Sequence 1 | Vonoprazan 20 mg: Treatment Sequence 2 | Vonoprazan 20 mg: Treatment Sequence 3 | Total |
|---|---|---|---|---|
| Mean | 35.1 ± 7.22 | 32.9 ± 8.51 | 35.8 ± 9.63 | 34.6 ± 8.27 |
| Sex: Female, Male(Participants) | Vonoprazan 20 mg: Treatment Sequence 1 | Vonoprazan 20 mg: Treatment Sequence 2 | Vonoprazan 20 mg: Treatment Sequence 3 | Total |
|---|---|---|---|---|
| Female | 5 | 2 | 4 | 11 |
| Male | 4 | 7 | 5 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Vonoprazan 20 mg: Treatment Sequence 1 | Vonoprazan 20 mg: Treatment Sequence 2 | Vonoprazan 20 mg: Treatment Sequence 3 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 6 | 2 | 3 | 11 |
| Not Hispanic or Latino | 3 | 7 | 6 | 16 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Vonoprazan 20 mg: Treatment Sequence 1 | Vonoprazan 20 mg: Treatment Sequence 2 | Vonoprazan 20 mg: Treatment Sequence 3 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 4 | 10 |
| White | 5 | 6 | 5 | 16 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2022 to primary completion in Jul 2022, 1 month.
Results were first posted in Mar 2024, 1 year 8 months after primary completion.
Of 28 industry-sponsored phase 1 interventional studies under Gastroesophageal Reflux, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's 1 month is below that.
Counting every sponsor, half of 34 studies reached it within 4 months; a quarter within 2 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vonoprazan
Phathom Pharmaceuticals, Inc.